Table 3.
Treatment outcomes
| Variable | Unit | Treated | Controls | RM ANOVA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Pre | Post | Change (%) | Simple main effect p | N | Pre | Post | Change (%) | Simple main effect p | Within subjects factor p | Between-subjects factor p | ||
| AMH | ng/ml | 20 | 10.74 ± 6.6 | 12.17 ± 7.1 | 13.30 | 0.029 | 10 | 11.8 ± 6.4 | 9.95 ± 6.4 | − 15.7 | 0.021 | 0.674 | 0.002 |
| Testost. | ng/dl | 22 | 53.91 ± 22.9 | 54.34 ± 22.9 | 0.8 | 0.878 | 10 | 55.2 ± 16.7 | 41.5 ± 19.0 | − 24.8 | 0.015 | 0.018 | 0.012 |
| SHBG | nM/L | 21 | 58.79 ± 23.8 | 55.5 ± 23.8 | − 5.6 | 0.27 | 10 | 52.1 ± 25.7 | 50.58 ± 28.1 | − 2.90 | 0.662 | 0.326 | 0.716 |
| FTI | units | 22 | 3.94 ± 2.4 | 3.98 ± 2.9 | 5.80 | 0.942 | 10 | 4.33 ± 1.9 | 3.51 ± 2.1 | − 19.9 | 0.196 | 0.363 | 0.320 |
| Hcy | μM/L | 21 | 11.91 ± 4.9 | 8.12 ± 2.3 | − 31.8 | 0.003 | 10 | 11.38 ± 4.9 | 12.11 ± 6.4 | 6.40 | 0.498 | 0.096 | 0.017 |
| Hcy > 12 | 21 | 8 | 1 | − 33.3 | 0.023 | 10 | 3 | 3 | 0 | 1.000 | |||
| 30.00% | 30.00% | ||||||||||||
| 38.10% | 4.80% | ||||||||||||
Significant p values are shown in bold